Investment Focus - The report highlights Amazon (AMZN US) as a top pick due to its leading position in the cloud industry with a 30% global market share, stable margin improvements, and strong demand for its T3 inference capabilities [1] - Alphabet (GOOGL US) is favored for its AI and advertising synergy, expected margin improvements in IaaS cloud services, and strong self-developed capabilities, although its stock price upside is currently limited [1] - Arista (ANET US) is recognized for its leadership in high-speed data center switches and expected revenue contributions from AI backend switch business, with a significant growth visibility [1] - Meituan (3690 HK) is noted for its strong cash flow generation ability and competitive cost structure, positioning it well in the face of industry competition [1] - Lenovo (992 HK) is highlighted for its record revenue in AI server business and significant growth potential compared to peers like Dell [2] - NVIDIA (NVDA US) is recognized for its strong financial performance and technological leadership in data center business, with a focus on emerging applications driving growth [2] - Tencent (700 HK) is expected to benefit significantly from AI advancements, with an upward revision in revenue and profit expectations for 2025 [2] - New Oriental (EDU US) is noted for its diverse revenue sources and strong brand recognition, supporting its high profit margins [3] - AIA (1299 HK) is favored for its steady growth in new business value and strong operational metrics, particularly in the ASEAN market [3] - Futu (FUTU US) is expected to see significant growth in paid user numbers and total AUM, supported by its low commission model and quality customer service [3] - The report emphasizes the potential of Chinese pharmaceutical companies like China Biologic Products (1177 HK) and Innovent Biologics (1801 HK) in their innovative drug pipelines and market leadership [4]

Market Overview - The Hong Kong stock market experienced a decline on August 1, with the Hang Seng Index falling by 1.07% to close at 24,507.81 points [1] - The Hang Seng Tech Index decreased by 1.02% to 5,397.40 points, while the National Enterprises Index dropped by 0.88% to 8,804.42 points [1] - The main board recorded a trading volume exceeding 254.6 billion HKD, with 608 stocks rising, 1,578 falling, and 972 remaining unchanged [1] Sector Performance - Most sectors saw declines, particularly in insurance, brokerage, biomedicine, and oil and gas [1] - Mixed performance was noted in banking, real estate, and coal sectors, while online retail, telecommunications services, and gold and precious metals sectors generally saw gains [1] Notable Stocks - Zijin Mining rose by 0.95%, while Shandong Gold fell by 0.21% [1] - NIO increased by 8.62%, and China Jinmao rose by 8.39% [1] - ZTO Express gained 7.44%, and Xiaomi Group increased by 0.47% [1] - China National Petroleum Corporation dropped by 5.87%, and Guotai Junan International fell by 10.78% [1] - In terms of significant gains, InnoCare Pharma surged by 30.91% [1] Top Traded Stocks - Tencent Holdings saw a decline of 2.73% with a trading volume exceeding 11.5 billion HKD [2] - Alibaba increased by 1.04%, with a trading volume over 8.8 billion HKD [2] - Meituan rose by 0.49%, with a trading volume exceeding 6.8 billion HKD [2]

Group 1 - China Biopharmaceutical announced a successful collaboration progress with Merck on LM-299, expecting to receive a $300 million technology transfer milestone payment soon [1] - The technology transfer for LM-299 was completed in July 2025, with Merck confirming the milestone payment in the third quarter [1] - CSPC Pharmaceutical reached an exclusive licensing agreement with Madrigal for the GLP-1 receptor agonist SYH2086, with a total deal value of up to $20.75 billion [2] Group 2 - Eli Lilly's drug Mounjaro (tirzepatide injection) received approval from China's National Medical Products Administration for a new indication to improve blood sugar control in adults with type 2 diabetes [3] - Hualan Pharmaceutical expects a profit of approximately RMB 1.184 billion for the first half of the year, following the successful transfer of commercialization tasks for Huataning [4] - WuXi AppTec reported a 101.92% increase in net profit to RMB 8.561 billion for the first half of the year, with revenue growth of 20.64% to RMB 20.799 billion [5] Group 3 - Heng Rui Medicine signed a collaboration agreement with GSK to advance innovative therapies in respiratory, autoimmune, inflammation, and oncology fields, with a potential total value of approximately $12 billion [6][7] - GSK will pay Heng Rui a $500 million upfront payment, with potential future milestone payments based on successful development and sales [7]

Core Viewpoint - The China Securities Index for Hong Kong Stock Connect Medical and Health Comprehensive Index has shown significant growth, with a year-to-date increase of 85.26% [1]. Group 1: Index Performance - The Shanghai Composite Index decreased by 0.37%, while the Hong Kong Stock Connect Medical and Health Comprehensive Index fell by 2.51%, closing at 3658.84 points with a trading volume of 24.507 billion yuan [1]. - Over the past month, the Hong Kong Stock Connect Medical and Health Comprehensive Index has risen by 24.02%, and over the last three months, it has increased by 47.29% [1]. Group 2: Index Composition - The index comprises 50 liquid and large-cap medical and health industry companies listed within the Hong Kong Stock Connect, reflecting the overall performance of these securities [1]. - The index was established on November 14, 2014, with a base point of 3000.0 [1]. Group 3: Top Holdings - The top ten holdings in the index are as follows: - Innovent Biologics (10.25%) - WuXi Biologics (9.23%) - BeiGene (8.95%) - CanSino Biologics (8.12%) - China Biologic Products (5.97%) - CSPC Pharmaceutical Group (5.77%) - JD Health (4.52%) - 3SBio (4.19%) - Hansoh Pharmaceutical (3.0%) - WuXi AppTec (2.85%) [1]. Group 4: Market and Sector Allocation - The index's holdings are entirely composed of securities listed on the Hong Kong Stock Exchange, with a 100% allocation to the medical and health sector [1].

Group 1 - The core viewpoint of the article revolves around China Biologic Products' acquisition of Lixin Pharmaceutical for approximately $680 million, raising questions about whether this high-priced acquisition will fill the innovation gap or lead to new challenges for the traditional pharmaceutical giant [2][21]. - The strategic intent behind the acquisition is highlighted, focusing on Lixin's significant licensing agreements with AstraZeneca and Merck, which are expected to generate substantial revenue [3][4]. - The financial pressure from the acquisition is evident, as the payment of around $350 million represents 69% of China Biologic's annual R&D expenditure, raising concerns about cash flow and operational sustainability [4][22]. Group 2 - Lixin Pharmaceutical's financial performance is scrutinized, revealing a sharp increase in revenue from $21,000 in 2024 to $4.218 billion in the first half of 2025, primarily due to licensing deals, while the company still reported losses in previous years [6][7]. - The uncertainty surrounding Lixin's R&D pipeline is discussed, with potential competition from other companies and the risk of not achieving commercial success for its innovative products [8][12]. - The challenges of integrating Lixin into China Biologic's operations are emphasized, particularly the need for effective management and the risk of losing key talent from Lixin's R&D team [10][11]. Group 3 - The article outlines the impact of policy changes on the commercialization of innovative drugs, including price negotiations and procurement policies that could threaten profit margins [13][14]. - The internationalization challenges faced by China Biologic are noted, as reliance on licensing agreements may lead to a loss of technological leverage in global markets [15][16]. - Valuation pressures and market skepticism are highlighted, with concerns that the high valuation of Lixin may not reflect its actual product value, leading to potential reevaluation of China Biologic's overall valuation [18][20].

【导读】港交所上市新规 8 月 4 日生效，阿里前董事会主席张勇履新港交所 中国基金报记者 郭玟君 8 月 1 日，香港三大股指全线下跌。香港恒生指数收跌 1.07% ，报 24507.81 点；恒生科技指数跌 1.02% ，报 5397.4 点；恒生中国 企业指数跌 0.88% ，报 8804.42 点。大市成交 2546.7 亿港元，南向资金大幅净买入超 122 亿港元。 8 月 1 日，香港《稳定币条例》正式生效，香港金管局此前发布的稳定币发行人监管制度也于同日刊宪。随着稳定币监管制度的正式生 效，香港市场参与者须遵守《稳定币条例》及相关指引。 港交所最新任命 阿里前董事会主席张勇又有新身份 8 月 1 日，香港交易所宣布 委任晨壹基金管理合伙人及阿里巴巴集团前董事会主席张勇先生 为香港交易所旗下中国业务咨询委员会的最 新成员。 中国石油化工股份跌 5.87% ，药明康德跌 3.78% ，中国石油股份跌 3.26% 。 | 序号 | 名称 | 代码 | 现价 | 涨跌 | 涨跌幅 ^ | 成交额 | 年初至今 | | --- | --- | --- | --- | --- | --- | --- | - ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國生物製藥有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01177 | 說明 | - | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 30,000,000,000 | HKD | | 0.025 HKD | | 750,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | 30,000,000,000 | | HKD | | 0.025 HKD | | 750,000,000 | 本月底法定/註冊股本總額： HK ...

Core Insights - The core breakthrough in China's biotechnology sector is the significant narrowing of the innovation gap with the U.S., reduced from 10 years to 3.7 years over the past decade [1][4][5] - Analysts warn that the biotechnology industry's valuation has become significantly overestimated, with valuation multiples now higher than those of U.S. biotech companies, suggesting that the market may have prematurely reassessed the industry's fundamental improvement prospects [1][25] Industry Transition - China's biotechnology industry is at a historic turning point, transitioning from being a "follower" to a key contributor in global "1-to-N" innovation [3] - By 2030, innovative drug sales are projected to account for 53% of China's pharmaceutical market, up from 29% in 2023, with a compound annual growth rate (CAGR) of 21% [3][14] Innovation Gap Reduction - The narrowing of the innovation gap is attributed to systematic capability improvements within China's biotechnology sector [6] - From 2020 to 2024, 112 new molecular entities were launched in China, representing about 25% of the global total, with nearly a quarter of U.S. FDA-approved drug categories also receiving domestic approval in China [6] Licensing Boom - The surge in external licensing activities reflects the growing global recognition of Chinese biotechnology [7] - In 2024, the total value of China's external licensing transactions is expected to exceed $50 billion, a significant increase from 2022, driven by unique competitive advantages in specific therapeutic areas [10] Cost and Speed Advantages - China's biotechnology sector has become a major contributor to global ADC (antibody-drug conjugates) innovation, with over 60% of global ADC clinical trials initiated in China in 2023 [12] - The cost advantage in clinical trials is notable, with Phase III trial costs per participant being about one-third of those in the U.S. ($25,000 vs. $69,000), and faster patient recruitment rates [12] Domestic Market Potential - The growth of China's biotechnology sector is significantly driven by domestic demand, with rural healthcare spending projected to reach approximately 2.4 trillion RMB by 2030 [13] - The urban-rural healthcare spending gap has narrowed from 63% to 53% over the past decade, with expectations that it will further reduce to 45% by 2030 [13] Pharmaceutical Companies' Evolution - Chinese pharmaceutical companies are increasingly participating in global markets, with traditional firms showing different characteristics and advantages compared to biotech companies [15] - The top 20 external licensing transactions in 2024-2025 will include 9 pharmaceutical companies, indicating their acceleration in globalization [15] Globalization Strategies - The globalization path for pharmaceutical companies is evolving from simple external licensing to more complex collaboration models, such as the "NewCo" model, which involves establishing overseas entities with shared equity [19] CDMO Industry Role - China's CDMO (Contract Development and Manufacturing Organization) industry is becoming increasingly important in the global pharmaceutical supply chain, with major players holding over 10% market share in both large and small molecule CDMO markets [21] - Key competitive advantages for Chinese CDMOs include cost efficiency (30-40% lower unit costs compared to Western facilities), speed, and large-scale production capabilities [23] Valuation Concerns - The biotechnology sector's valuation has seen a significant revaluation, with average price-to-earnings ratios for H-shares rising from 2.2x to 4.5x since the beginning of the year, surpassing U.S. biotech's approximately 2.5x [25]

格隆汇8月1日丨中国生物制药(01177.HK)宣布，公司将于2025年8月18日（星期一）举行董事会会议， 藉以批准（其中包括）刊发公司及其附属公司截至2025年6月30日止六个月期间的未经审核中期业绩， 以及考虑派发中期股息（如有）。 ...

（於開曼群島註冊成立之有限公司） 網站：www.sinobiopharm.com （股份編號：1177） 董事會召開通知 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 中國生物製藥有限公司 公司秘書 陳凱年 香港，二零二五年八月一日 於本公告日期，本公司董事會包括六位執行董事，即謝其潤女士、謝炳先生、鄭翔玲女士、謝承潤 先生、謝炘先生及田舟山先生，以及五位獨立非執行董事，即陸正飛先生、李大魁先生、魯紅女 士、張魯夫先生及李國棟醫生。 中國生物製藥有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將於二零二五年八月十八日 （星期一）舉行董事會會議，藉以批准（其中包括）刊發本公司及其附屬公司截至二零二五年六月三十日 止六個月期間之未經審核中期業績，以及考慮派發中期股息（如有）。 承董事會命 ...